tiprankstipranks
Advertisement
Advertisement
Denali Regains DNL593 Rights After Takeda Collaboration Ends
PremiumCompany AnnouncementsDenali Regains DNL593 Rights After Takeda Collaboration Ends
29d ago
Denali Therapeutics Secures $200 Million Royalty Funding
Premium
Company Announcements
Denali Therapeutics Secures $200 Million Royalty Funding
1M ago
Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank
Premium
The Fly
Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank
1M ago
Denali Therapeutics price target raised to $32 from $29 at Baird
PremiumThe FlyDenali Therapeutics price target raised to $32 from $29 at Baird
1M ago
Denali Therapeutics: AVLAYAH’s Superior Efficacy, BBB Shuttle Platform, and Robust Pipeline Support Buy Rating and Higher Target
Premium
Ratings
Denali Therapeutics: AVLAYAH’s Superior Efficacy, BBB Shuttle Platform, and Robust Pipeline Support Buy Rating and Higher Target
1M ago
Denali Therapeutics: Avlayah Launch and Platform De-Risking Support Commercial Upside and Higher Valuation
Premium
Ratings
Denali Therapeutics: Avlayah Launch and Platform De-Risking Support Commercial Upside and Higher Valuation
1M ago
Denali Therapeutics: Underappreciated Hunter Syndrome Launch and 2026 CNS Pipeline Catalysts Support Buy Rating
PremiumRatingsDenali Therapeutics: Underappreciated Hunter Syndrome Launch and 2026 CNS Pipeline Catalysts Support Buy Rating
2M ago
Denali Therapeutics reports Q4 EPS (73c), consensus (75c)
Premium
The Fly
Denali Therapeutics reports Q4 EPS (73c), consensus (75c)
2M ago
Denali Therapeutics initiated with a Peer Perform at Wolfe Research
Premium
The Fly
Denali Therapeutics initiated with a Peer Perform at Wolfe Research
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100